2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2647 Real-world healthcare resource use and economic burden of B-cell acute lymphoblastic leukemia by treatment line in the United States

Neil D Palmisiano, MD, MS, Yazan Barqawi, PhD, PharmD2, Julia Ma, MPH3, Debbie Adkins, PhD, CStat4, Yu-Hua Fu5, Jesica Levingston Mac leod, PhD6, Victoria Otero, MD7
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 Astrazeneca, Gaithersburg, Maryland, United States
3 Astrazeneca, Mississauga, Ontario, Canada
4 Astrazeneca, Cambridge, Cambridge, United Kingdom
5 AstraZeneca, Gaithersburg, Maryland, United States
6 Astrazeneca, Cambridge, Cambridge, United Kingdom
7 AstraZeneca, Gaithersburg, Maryland, United States

Introduction

In the United States (US), approximately 6,250 new acute lymphoblastic leukemia (ALL) cases and 1,600 deaths are expected in 2026; B-cell ALL (B-ALL) accounts for about 75% of cases. Patients with relapsed/refractory B-ALL often require advanced therapies, including blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor T-cell therapy (CAR-T), which are associated with high acquisition, administration, and supportive care costs. Prior economic evidence is limited by pediatric-focused populations, pre-CAR-T treatment eras, and non-US settings. This study quantified all-cause and B-ALL-related healthcare resource utilization (HCRU) and costs by line of therapy from a US payer perspective.

Methods

This is an observational, retrospective study using IQVIA PharMetrics Plus administrative claims with mortality linked ambulatory electronic medical records. Adults ≥18 years with B-ALL and ≥1 claim for a National Comprehensive Cancer Network recommended first-line therapy (index date=earliest B-ALL treatment claim) between 01Jan2015 and 31Dec2025 were included; continuous health insurance enrollment ≥6 months pre-index baseline period (≤30day allowed gap) was required. Patients receiving blinatumomab, inotuzumab, or CAR-T in second line (2L), third line (3L), or fourth line or later (4L+) were evaluated. Follow-up continued until the earliest of death, disenrollment, or 31Dec2025. Outcomes were all-cause and B-ALL-attributed HCRU and costs, per patient per month (PPPM) overall and by line of therapy. HCRU included inpatient visits, outpatient visits, emergency department (ED) visits, and medication fills. Costs were standardized to the 2025 USD and summarized overall as well as by care setting.

Results

We included 1,611 adults with B-ALL who initiated 1L treatment. Mean age was 47.9 years, 54.4% were male, and 82.7% were commercially insured. During the follow-up period (median follow-up 18.2 months), 417 received 2L, 301 received 3L, and 161 received 4L+ treatment. Among these patients, 332, 180, and 72 received either blinatumomab, inotuzumab, or CAR-T in 2L, 3L, and 4L+, respectively. Outpatient visits and medication fills were the most frequent forms of utilization, while ED visits were infrequent. Median all-cause outpatient visits PPPM were 5.4 in 2L, 4.9 in 3L, and 4.6 in 4L+; corresponding B-ALL-related values were 4.5, 4.2, and 3.1. Median all-cause medication fills PPPM were 9.3, 8.7, and 7.6 in 2L, 3L, and 4L+, respectively; B-ALL-related medication fills were 3.5, 2.5, and 2.4. Inpatient utilization was less frequent on a PPPM basis, but it remained an important contributor to overall burden. Median all-cause inpatient visits PPPM were 0.6 in 2L, 0.6 in 3L, and 0.5 in 4L+, with comparable B-ALL-related estimates of 0.5, 0.6, and 0.5, respectively. The relatively lower inpatient HCRU may partly reflect inclusion of the index hospitalization in the baseline period. Total median all-cause costs PPPM were highest in 2L at $94,214, decreasing to $57,091 in 3L and $34,293 in 4L+; B-ALL-related median total costs were $93,221, $58,247, and $33,320, respectively. Medication costs were the largest cost component, particularly in 2L, with all-cause median PPPM medication costs of $62,368, $23,193, and $16,183 in 2L, 3L, and 4L+; corresponding B-ALL-related medication costs were $60,415, $25,184, and $17,361. Inpatient costs were also substantial, with all-cause median PPPM costs of $12,247 in 2L, $30,196 in 3L, and $8,568 in 4L+, and similar B-ALL-related estimates. Results for 4L+ should be interpreted cautiously because of small sample size.

Conclusion

Among US adult patients with B-ALL treated with blinatumomab, inotuzumab, or CAR-T, the economic burden was substantial across treatment lines, with a notably higher HCRU and cost in 2L treatment. Most HCRU and costs were directly attributable to B-ALL-related care, as shown by the close alignment between all-cause and disease-related estimates. Medication costs were the primary driver of total monthly costs, while inpatient care also contributed meaningfully, particularly in earlier lines. These findings highlight the considerable payer burden associated with advanced B-ALL treatment in routine US practice.

Neil D Palmisiano, MD, MS: AbbVie - Research Funding; Rigel - Consultancy (Includes expert testimony); FoundationOne - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)